

FAQ: Ambulatory Care Clinical Pharmacist Peer Review Date of Publication: August 2019

Contact:
Melanie R. Smith, Pharm.D., BCACP, DPLA
Director, Section of Ambulatory Care Practitioners
sections@ashp.org

Purpose: This document serves as a generalized evaluation form of patient care note documentation in the ambulatory care practice setting. The <u>Ambulatory Care Summit</u> recommendations state that ambulatory care pharmacists performing clinical work must provide and document the provision of coordinated, integrated, and comprehensive services and these records must be accessible to all members of the healthcare team. Peer review serves as a process of quality control and involves scrutiny from clinicians within the same field reviewing the work of another for expected documentation, interventions, and billing elements.

This form follows the patient care process approach and includes the elements recommended by the <u>Joint Commission of Pharmacy Practitioners</u>. The step-wise process serves to ensure patient-centered care is provided and other providers can follow the actions of the ambulatory care pharmacist.

Published on behalf of the ASHP Section of Ambulatory Care Practitioners

Advisory Group on Clinical Practice Advancement



Ambulatory Care Clinical Pharmacist Peer Review

Areas of Applicability

This example document may be applicable in the following ambulatory care pharmacy practice settings*:

- Direct patient care or disease state management
 - o e.g. anticoagulation, diabetes, hypertension, hyperlipidemia
- Transitions of care services
- Population health services
- Medicare annual wellness services
- Chronic care management services
- Medication management services



Joint Commission of Pharmacy Practitioners. Pharmacists' Patient Care Process. May 29, 2014. Available at: https://icpp.net/wp-content/uploads/2016/03/PatientCareProcess-with-supporting-organizations.pdf.

Additional Considerations

- Consider the frequency of the peer review (e.g. quarterly, bi-annual) as these reviews may aid in the annual review of an individual provider, resident, new clinical service, and/or department.
- The peer review form may be completed by an individual reviewer or a team.
- The peer review process is often blinded. It is important to pair pharmacists of similar practice settings (i.e. a transitions-of-care pharmacist should not be assigned to an oncology pharmacist).
- Ensure pharmacists have access to appropriate practice-setting policies and evidence-based medicine to provide objective and actionable comments in the review.
- Create a policy to audit and review the peer review process itself. As practice models evolve and change, this document should adapt as well.

^{*}Suggested list. May adjust based upon scope of practice and/or collaborative practice agreement as needed.



Example Peer Review Template

Pharmacist being evaluated:	
Evaluator:	
Date of review:	
Date and time of encounter being reviewed:	
Encounter type or reason for visit:	

		Documentation	Evaluation	Comments
		Is the reason for the referral/visit clearly stated?	Yes□ No□ N/A□	
:	Collect	Is the subjective information clearly and concisely stated?	Exceeds Meets Does not Meet	
		Is the objective information relevant and clearly stated?	Exceeds Meets Does not Meet	
	Assess	Is there clear evidence of medication list reconciliation or review?	Exceeds Meets Does not Meet	
•	As	Is the assessment clear and complete?	Exceeds Meets Does not Meet	
	Plan	Is the plan clearly stated and prioritized appropriately? (Includes drug name, dose, route, frequency, etc.)	Exceeds Meets Does not Meet	
	L	Is the follow-up plan clearly stated?	Exceeds Meets Does not Meet	

Is patient education clearly documented?

Exceeds Does not Meet

	Order Authorization & Scope of Practice	Evaluation	Comments
	Medications and/or labs are ordered correctly (i.e. dosage, SIG, refills, day supply, etc.).	Yes⊡ No⊡ N/A⊡	
Implement	Are medication and/or lab orders consistent with the applicable authorization (eg. CDTM, CPA, referral)?	Yes⊡ No⊡ N/A⊡	
	Is there indication of verbal or written authorization for medication and/or lab orders that fall outside the applicable scope of prescriptive authority?	Yes⊡ No⊡ N/A⊡	



Is the documentation appropriate for the level of service provided?	Yes⊡ No⊡ N/A⊡	
Does the selected CPT code match the level of service provided?	Yes⊡ No⊡ N/A⊡	
Was the progress note forwarded to the provider and signed within 48 hours?	Yes⊡ No⊡ N/A⊡	

	Therapeutic Decision Making	Evaluation	Comments
Collect	Is there evidence of a consideration for patient lifestyle habits, preferences, beliefs, health goals, and socioeconomic factors?	Exceeds Meets Does not Meet	



Assess	Is the pharmacotherapy assessment appropriate and accurate?	Exceeds Meets Does not Meet	
Plan	Are goals of care clearly stated and individualized?	Exceeds Meets Does not Meet	
ğ	Is the therapeutic plan appropriate based on current standards of medical care and evidence-based guidelines?	Exceeds Meets Does not Meet	
Implement	Is follow-up scheduled at an appropriate (i.e. interval, labs ordered, etc.) interval?	Exceeds Meets Does not Meet	



Patient Safety & Legal Considerations	Evaluation	Comments
Are there any patient safety concerns with the plan as stated or enacted?	Yes⊡ No⊡ N/A⊡	
Are there any potential risk management/liability concerns with the note, as stated?	Yes□ No□ N/A□	
Miscellaneous	Evaluation	Comments
Does the note contain unapproved abbreviations? (https://www.ismp.org/recommendations/error-prone-abbreviations-list)	Yes⊡ No⊡ N/A⊡	
Is the documentation completed in a timely manner?	Yes□ No□ N/A□	

Overall Level Assignment: A / B / C / D

Level Assignment Definitions

- Level A: All criteria met; Optimal or near optimal care of the patient where most other practitioners would have managed the case similarly
- Level B: Criteria partially met; Minor discrepancies in the care of the patient (may benefit the patient, but was not the optimal choice)
- Level C: Criteria mostly not met; Significant discrepancies in the care of the patient, but not requiring management action (may not result in patient harm but likely will not advance therapy)
- Level D: Criteria not met; Serious discrepancies in the care of the patient requiring management attention (may result in patient harm)

Additional Comments:

Pharmacist Signature/Date	Peer Evaluator Signature/Date



Contributing Authors

Ben Berrett, BCPS, BCACP, BC-ADM
Manager, Pharmacy Primary Care Services
University of Utah Health
Salt Lake City, Utah

Lauren Hickman, Pharm.D., BCACP
Ambulatory Care Clinical Pharmacy Specialist
Johns Hopkins Hospital
Baltimore, MD

Kelly Mullican, Pharm.D., BCACP
Primary Care Clinical Pharmacy Specialist
Kaiser Permanente
Washington, DC

Edward Saito, Pharm.D., BCACP
Assistant Professor
Pacific University School of Pharmacy
Hillsboro, OR

Kong Wong, Pharm.D., BCACP
Transitional Care Clinical Pharmacist
Kaiser Permanente
Arlington, VA

Paige Carson, Pharm.D., CDE, BCPS, CPP Clinical Leader, Residency Program Director Atrium Health Charlotte, NC

Hanlin Li, Pharm.D., BCACP
Clinical Pharmacy Manager, Ambulatory Care
NewYork-Presbyterian Hospital/Columbia University Irving
Medical Center
New York, NY

Margie Padilla, Pharm.D., CDE, BCACP Clinical Associate Professor UTEP School of Pharmacy El Paso, TX

Daniel Truelove, Pharm.D., BCPS (AQ-ID), BCACP, AAHIVP
Assistant Director of Pharmacy, Ambulatory Care / Specialty
University of Tennessee Medical Center
Knoxville, TN

<u>Peer Reviewer</u> Brittany Thompson, PharmD

Clinical Pharmacy Specialist, Ambulatory Care Medical University of South Carolina (MUSC) Affiliate Assistant Professor, MUSC University of South Carolina College of Pharmacy